Microbiome modulates immunotherapy response in cutaneous squamous cell carcinoma.
SKH1 hairless mice
skin microbiome
squamous cell carcinoma
Journal
Experimental dermatology
ISSN: 1600-0625
Titre abrégé: Exp Dermatol
Pays: Denmark
ID NLM: 9301549
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
07
06
2023
received:
15
02
2023
accepted:
13
06
2023
pmc-release:
01
10
2024
medline:
12
10
2023
pubmed:
23
6
2023
entrez:
23
6
2023
Statut:
ppublish
Résumé
The gut microbiome is increasingly recognized to alter cancer risk, progression and response to treatments such as immunotherapy, especially in cutaneous melanoma. However, whether the microbiome influences immune checkpoint inhibitor (ICI) immunotherapy response to non-melanoma skin cancer has not yet been defined. As squamous cell carcinomas (SCC) are in closest proximity to the skin microbiome, we hypothesized that the skin microbiome, which regulates cutaneous immunity, might affect SCC-associated anti-PD1 immunotherapy treatment response. We used ultraviolet radiation to induce SCC in SKH1 hairless mice. We then treated the mice with broad-band antibiotics to deplete the microbiome, followed by colonisation by candidate skin and gut bacteria or persistent antibiotic treatment, all in parallel with ICI treatment. We longitudinally monitored skin and gut microbiome dynamics by 16S rRNA gene sequencing and tumour burden by periodic tumour measurements and histologic assessment. Our study revealed that antibiotics-induced abrogation of the microbiome reduced the tumour burden, suggesting a functional role of the microbiome in non-melanoma skin cancer therapy response.
Identifiants
pubmed: 37350109
doi: 10.1111/exd.14864
pmc: PMC10592435
mid: NIHMS1913231
doi:
Substances chimiques
Anti-Bacterial Agents
0
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1624-1632Subventions
Organisme : NIAMS NIH HHS
ID : R01 AR078634
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI142733
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA034196
Pays : United States
Organisme : NIAID NIH HHS
ID : K22 AI119231
Pays : United States
Organisme : NINDS NIH HHS
ID : U54 NS105539
Pays : United States
Organisme : NIAMS NIH HHS
ID : R21 AR075174
Pays : United States
Organisme : NIGMS NIH HHS
ID : DP2 GM126893
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Biomedicines. 2018 Jan 02;6(1):
pubmed: 29301290
Zentralbl Bakteriol. 1990 Dec;274(3):289-98
pubmed: 2090145
J Cancer. 2020 Jun 28;11(17):5135-5149
pubmed: 32742461
Eur J Med Chem. 2020 Mar 1;189:112050
pubmed: 31954879
Photodermatol Photoimmunol Photomed. 2018 Nov;34(6):405-414
pubmed: 29974533
Nature. 2015 Apr 2;520(7545):104-8
pubmed: 25539086
J Immunother Cancer. 2019 Nov 6;7(1):287
pubmed: 31694714
J Photochem Photobiol B. 2020 Apr;205:111847
pubmed: 32172138
Science. 2021 Mar 26;371(6536):
pubmed: 33766858
ESMO Open. 2020 Sep;5(5):e000803
pubmed: 32900789
J Res Med Sci. 2018 Feb 20;23:14
pubmed: 29531566
Nat Med. 2022 Mar;28(3):535-544
pubmed: 35228751
J Dermatol Sci. 2009 Jan;53(1):10-8
pubmed: 18938063
Science. 2013 Nov 22;342(6161):971-6
pubmed: 24264990
Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):472-8
pubmed: 19155437
Eur J Med Chem. 2020 Sep 1;201:112510
pubmed: 32592915
mBio. 2018 Oct 9;9(5):
pubmed: 30301852
Oncol Lett. 2019 May;17(5):4068-4084
pubmed: 30944600
Infect Immun. 2021 Mar 17;89(4):
pubmed: 33468585
Science. 2012 Aug 31;337(6098):1115-9
pubmed: 22837383
Carcinogenesis. 2014 Feb;35(2):424-31
pubmed: 24031027
J Invest Dermatol. 2019 Aug;139(8):1837-1840.e3
pubmed: 30742806
PLoS One. 2011;6(12):e29020
pubmed: 22216160
J Invest Dermatol. 2022 Oct;142(10):2773-2782.e16
pubmed: 35390349
Oncoimmunology. 2019 Sep 23;8(12):e1665973
pubmed: 31741763
Trends Cancer. 2020 Mar;6(3):192-204
pubmed: 32101723
Science. 2018 Jan 5;359(6371):104-108
pubmed: 29302014
Cancers (Basel). 2020 Feb 26;12(3):
pubmed: 32111012
Science. 2015 Nov 27;350(6264):1084-9
pubmed: 26541606
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
Science. 2021 Feb 5;371(6529):595-602
pubmed: 33542131
Nat Immunol. 2020 Sep;21(9):1034-1045
pubmed: 32661363
JAMA Oncol. 2019 Dec 1;5(12):1774-1778
pubmed: 31513236
Dermatol Clin. 2017 Jan;35(1):1-9
pubmed: 27890233
Science. 2015 Nov 27;350(6264):1079-84
pubmed: 26541610
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
PLoS One. 2015 Apr 28;10(4):e0124384
pubmed: 25919398
Exp Dermatol. 2013 Sep;22(9):587-92
pubmed: 23947673
Front Microbiol. 2022 Jan 25;12:789042
pubmed: 35145494
Anticancer Res. 2017 Jun;37(6):3195-3200
pubmed: 28551664
Semin Immunopathol. 2007 Apr;29(1):15-26
pubmed: 17621951
Eur Urol. 2020 Oct;78(4):544-545
pubmed: 32811714